Synta trumpets interim data for breast cancer hopeful; Emergent buying Cangene for $222M;

@FierceBiotech: In January, Levin dumped Teva's immunotherapy program. Now, checkpoint receptor drugs are all the rage. More | Follow @FierceBiotech

@JohnCFierce: Galderma Labs axing staff in U.S. shakeup after president exits (gee, the rumors were true). News | Follow @JohnCFierce

@DamianFierce: Imagine being the Novartis worker who picked up Retrophin's call. "Hey, so, remember Syntocinon?" | Follow @DamianFierce

@EmilyMFierce: Congressional budget deal would restore NIH sequester cuts. Coverage | Follow @EmilyMFierce

> Synta Pharmaceuticals ($SNTA) is touting early results for the breast cancer-treating ganetespib, its lead candidate, pointing to interim Phase II data in which the treatment posted a 75% response rate among HER2-positive patients. Release

> Rockville, MD's Emergent BioSolutions ($EBS) has signed a deal to buy Cangene for $222 million, acquiring the company's line of biodefense therapeutics and infectious disease treatments. More

Medical Device News

@FierceMedDev: Avinger draws new financing to back testing of light-enhanced PAD catheter. Article | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical won a CE mark for a larger size of its Portico heart valve, adding to a now-crowded competition. More | Follow @MarkHFierce

@MichaelGFierce: AdvaMed, MDMA commend congressional budget deal as vote approaches. Story | Follow @MichaelGFierce

@GalenMoore: Senesco Announces up to $25.2 Million Equity Financing. Release | Follow @GalenMoore

> Boston Scientific's Watchman stroke-fighting device wins overwhelming FDA panel support. Piece

> T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up. News

Pharma News

@FiercePharma: India's Lupin already launched its copies of Eli Lilly's $5B antidepressant, Cymbalta, in U.S. Half-dozen companies got FDA nod. Poor Lilly. | Follow @FiercePharma

@EricPFierce: Merck KGaA's Allergopharma unit building a €40M plant near Hamburg that will make #allergy meds for China. Release | Follow @EricPFierce

@CarlyHFierce: Here come the Cymbalta copies. FDA approves generics from Teva, Sun, Dr. Reddy's, Lupin and others. Release | Follow @CarlyHFierce

> Think fast: A new cognition study could add $350M to Lundbeck's Brintellix sales. News

> D-Day for Eli Lilly: Generic foes arrive for $5B antidepressant Cymbalta. Article

Vaccines News

> GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine. Story

> Novartis awaits pivotal Bexsero decisions in Canada and Europe. Piece

> Genocea begins a PhI trial of its rival to Pfizer's Prevnar. News

> AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval. More

> Pentagon tasks Pfizer with radically rethinking vaccine development. Article

> Lundbeck teams with Otsuka on Alzheimer's vaccine development. Item

Pharma Manufacturing News

> ScinoPharma's $113 million China API plant ready to go. News

> Merck KGaA targets China with a planned €40M allergy plant. More

> FDA stationing 10 new drug inspectors in China. Story

> GSK's new manufacturing investments in the U.K. now pass $1 billion. Article

> Cardinal, CVS JV creates more upheaval in U.S. drug supply chain. Piece

> FDA warns NJ lotion maker: Your water does not meet specs. Item

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.